Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies

Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies, Levetiracetam (LEV) was approved in 1999 by the US Food and Drug Administration (FDA) for the treatment of seizure disorders., Levetiracetam (LEV) was approved in 1999 by the US Food and Drug Administration (FDA) for the treatment of seizure disorders. It is a second-generation antiepileptic drug (AED) with a unique mechanism - it acts by binding to specific sites on the nerve cell surfaces [1], thus it inhibits the burst firing without affecting the normal neuronal excitability, suggesting that it selectively prevents the hyper synchronisation of epileptiform burst firing and propagation of seizure activity [2]. The FDA-labelled indications of LEV include myoclonic seizure, partial seizure, status epilepticus, and tonic-clonic seizures, and off-labelled indications of LEV include prophylactic treatment of migraine, single-drug therapy in partial seizure, and also the treatment of status epilepticus as a second-line agent [2]., admin,